title: Anti-HuC and -HuD autoantibodies are differential sero-diagnostic markers             for small cell carcinoma from large cell neuroendocrine carcinoma of the lung.
abstract: Aiming to identify novel sero-diagnostic markers for neuroendocrine carcinomas             of the lung, the two-dimensional gel electrophoresis-immunoblot method was used             to analyze tumor-associated autoantibodies in patients with small cell lung carcinoma             (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Several autoantigens were             revealed and anti-HuC autoantibody was detected only in sera of SCLC patients.             Since Hu family proteins including HuC are well-known causes of paraneoplastic             encephalomyelitis/sensory neuronopathy (PEM/SN), the expression of HuC as well             as HuD mRNAs and their proteins was studied in 11 lung cancer cell lines. The             expression of HuC and HuD mRNAs and proteins was only detected in SCLC- and LCNEC-derived             cells. To validate the existence of anti-HuC and -HuD auto-antibodies, we studied             a large number of sera including those from lung cancer patients employing dot             blot analysis. Anti-HuC and -HuD autoantibodies were detected only in SCLC cases             with or without PEM/SN, and not in the sera of LCNEC patients. The mechanism leading             to different anti-HuC and -HuD autoantibody production between SCLC and LCNEC             is unclear; however, the results from the present and previous studies suggest             that anti-HuC and -HuD auto-antibodies are novel differential sero-diagnostic             markers for SCLC from LCNEC.
authors.affiliation: Department of Applied Tumor Pathology, Kitasato University Graduate                     School of Medical Sciences, Kanagawa, Japan.
authors.forename: Toshihide
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ryuge
authors.forename: Makoto
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Taihei
authors.initials: T
authors.lastname: Kageyama
authors.forename: Manabu
authors.initials: M
authors.lastname: Hattori
authors.forename: Naoki
authors.initials: N
authors.lastname: Goshima
authors.forename: Shi-Xu
authors.initials: SX
authors.lastname: Jiang
authors.forename: Makoto
authors.initials: M
authors.lastname: Saegusa
authors.forename: Akira
authors.initials: A
authors.lastname: Iyoda
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Satoh
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sato
mesh_terms: D019540:Area Under Curve; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D018287:Carcinoma, Large Cell / Q000097:blood / Q000175:diagnosis*; D018278:Carcinoma, Neuroendocrine / Q000097:blood / Q000175:diagnosis*; D018288:Carcinoma, Small Cell / Q000097:blood / Q000175:diagnosis*; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D003937:Diagnosis, Differential; D051959:ELAV Proteins / Q000276:immunology; D000067778:ELAV-Like Protein 3; D000067779:ELAV-Like Protein 4; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis*; D012372:ROC Curve
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D051959:ELAV Proteins; D000067778:ELAV-Like Protein 3; D000067779:ELAV-Like Protein 4; C490264:ELAVL3 protein, human; C498010:ELAVL4 protein, human